MRI Posttreatment Surveillance for Head and Neck Squamous Cell Carcinoma: Proposed MR NI-RADS Criteria

References

1. 1.↵
   1. Aiken AH,
   2. Rath TJ,
   3. Anzai Y, et al

   . ACR Neck Imaging Reporting and Data Systems (NI-RADS): a white paper of the ACR NI-RADS Committee. J Am Coll Radiol 2018;15:1097–08 doi:10.1016/j.jacr.2018.05.006 pmid:29983244

   CrossRefPubMed
2. 2.↵
   1. Aiken AA,
   2. Farley A,
   3. Baugnon KL, et al

   . Implementation of a novel surveillance template for head and neck cancer: Neck Imaging Reporting and Data System (NI-RADS). J Am Coll Radiol 2016;13:743–46 doi:10.1016/j.jacr.2015.09.032 pmid:26577876

   CrossRefPubMed
3. 3.↵
   1. Wangaryattawanich P,
   2. Branstetter BF,
   3. Hughes M, et al

   . Negative predictive value of NI-RADS category 2 in the first posttreatment FDG-PET/CT in head and neck squamous cell carcinoma. AJNR Am J Neuroradiol 2018;39:1884–88 doi:10.3174/ajnr.A5767 pmid:30166429

   Abstract/FREE Full Text
4. 4.↵
   1. Krieger DA,
   2. Hudgins PA,
   3. Nayak GK, et al

   . Initial performance of NI-RADS to predict residual or recurrent head and neck squamous cell carcinoma. AJNR Am J Neuroradiol 2017;38:1193–99 doi:10.3174/ajnr.A5157 pmid:26577876

   Abstract/FREE Full Text
5. 5.↵
   1. Aiken AH,
   2. Hudgins PA

   . Neck Imaging Reporting and Data System. Magn Reson Imaging Clin N Am 2018;26:51–62 doi:10.1016/j.mric.2017.08.004 pmid:29128006

   CrossRefPubMed
6. 6.↵
   1. Ailianou A,
   2. Mundada P,
   3. De Perrot T, et al

   . MRI with DWI for the detection of posttreatment head and neck squamous cell carcinoma: why morphologic MRI criteria matter. AJNR Am J Neuroradiol 2018;39:748–55 doi:10.3174/ajnr.A5548 pmid:29449279

   Abstract/FREE Full Text
7. 7.↵
   1. Vaid S,
   2. Chandorkar A,
   3. Atre A, et al

   . Differentiating recurrent tumours from post-treatment changes in head and neck cancers: does diffusion-weighted MRI solve the eternal dilemma? Clin Radiol 2017;72:74–83 doi:10.1016/j.crad.2016.09.019 pmid:27789026

   CrossRefPubMed
8. 8.↵
   1. King AD,
   2. Keung CK,
   3. Yu KH, et al

   . T2-weighted MR imaging early after chemoradiotherapy to evaluate treatment response in head and neck squamous cell carcinoma. AJNR Am J Neuroradiol 2013;34:1237–41 doi:10.3174/ajnr.A3378 pmid:23306012

   Abstract/FREE Full Text
9. 9.↵
   1. Becker M,
   2. Varoquaux D,
   3. Combescure C, et al

   . Local recurrence of squamous cell carcinoma of the head and neck after radio(chemo)therapy: diagnostic performance of FDG-PET/MRI with diffusion-weighted sequences. Eur Radiol 2018;28:651–63 doi:10.1007/s00330-017-4999-1 pmid:28812148

   CrossRefPubMed
10. 10.↵
    1. Jajodia A,
    2. Aggarwal D,
    3. Chaturvedi AK, et al

    . Value of diffusion MR imaging in differentiation of recurrent head and neck malignancies from post treatment changes. Oral Oncol 2019;96:89–96 doi:10.1016/j.oraloncology.2019.06.037 pmid:31422219

    CrossRefPubMed
11. 11.↵
    1. Connolly M,
    2. Srinivasan A

    . Diffusion-weighted imaging in head and neck cancer: technique, limitations, and applications. Magn Reson Imaging Clin N Am 2018;26:121–33 doi:10.1016/j.mric.2017.08.011 pmid:29128000

    CrossRefPubMed
12. 12.↵
    1. Eisenhauer EA,
    2. Therasse P,
    3. Bogaerts J, et al

    . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–47 doi:10.1016/j.ejca.2008.10.026 pmid:19097774

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Tshering Vogel DW,
    2. Zbaeren P,
    3. Geretschlaeger A, et al

    . Diffusion-weighted MR imaging including bi-exponential fitting for the detection of recurrent or residual tumour after (chemo)radiotherapy for laryngeal and hypopharyngeal cancers. Eur Radiol 2013;23:562–69 doi:10.1007/s00330-012-2596-x pmid:22865270

    CrossRefPubMed
14. 14.↵
    1. Zhou Q,
    2. Zeng F,
    3. Ding Y, et al

    . Meta-analysis of diffusion-weighted imaging for predicting locoregional failure of chemoradiotherapy in patients with head and neck squamous cell carcinoma. Mol Clin Oncol 2018;8:197–203 doi:10.3892/mco.2017.1504 pmid:29423223

    CrossRefPubMed
15. 15.↵
    1. Fujima N,
    2. Yoshida D,
    3. Sakashita T, et al

    . Residual tumour detection in post-treatment granulation tissue by using advanced diffusion models in head and neck squamous cell carcinoma patients. Eur J Radiol 2017;90:14–19 doi:10.1016/j.ejrad.2017.02.025 pmid:28583625

    CrossRefPubMed
16. 16.↵
    1. Abdel Razek AAK,
    2. Kandeel AY,
    3. Soliman N, et al

    . Role of diffusion-weighted echo-planar MR imaging in differentiation of residual or recurrent head and neck tumors and posttreatment changes. AJNR Am J Neuroradiol 2007;28:1146–52 doi:10.3174/ajnr.A0491 pmid:17569975

    Abstract/FREE Full Text
17. 17.↵
    1. Hsu D,
    2. Chokshi FH,
    3. Hudgins PA, et al

    . Predictive value of first posttreatment imaging using standardized reporting in head and neck cancer. Otolaryngol Head Neck Surg 2019;161:978–85 doi:10.1177/0194599819865235 pmid:31331239

    CrossRefPubMed
18. 18.↵
    1. Wangaryattawanich P,
    2. Branstetter BF,
    3. Ly JD, et al

    . Positive predictive value of neck imaging reporting and data system categories 3 and 4 post treatment FDG-PET/CT in head and neck squamous cell carcinoma. AJNR Am J Neuroradiol 2020;41:1070–75 doi:10.3174/ajnr.A6589 pmid:32467187

    Abstract/FREE Full Text
19. 19.↵
    1. Chung SR,
    2. Choi YJ,
    3. Suh CH, et al

    . Diffusion-weighted magnetic resonance imaging for predicting response to chemoradiation therapy for head and neck squamous cell carcinoma: a systematic review. Korean J Radiol 2019;20:649–61 doi:10.3348/kjr.2018.0446 pmid:30887747

    CrossRefPubMed
20. 20.
    1. Amin MB,
    2. Edge SB,
    3. Greene FL, et al

    . AJCC Cancer Staging Manual. Springer; 2017.